Search Result

Results for "

Tetraxetan

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Linker (1) Biochemical Assay Reagents (4) Drug Derivative (1) Drug-Linker Conjugates for ADC (1) FAP (3) Neurokinin Receptor (1) Peptide-Drug Conjugates (PDCs) (1) Radionuclide-Drug Conjugates (RDCs) (4) Reference Standards (1) Somatostatin Receptor (1)
By Research Areas:	Cancer (11)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-117410

Vipivotide tetraxetan Maximum Cited Publications 17 Publications Verification PSMA-617	Drug-Linker Conjugates for ADC	Cancer
Vipivotide tetraxetan (PSMA-617) is a high potent prostate-specific membrane antigen (PSMA) inhibitor, with a K_i of 0.37 nM. Vipivotide tetraxetan (PSMA-617) is designed consisting of three components: the pharmacophore Glutamate-urea-Lysine, the chelator DOTA able to complex both 68Ga or 177Lu, and a linker connecting these two entities. Glutamate-urea-Lysine is the selective pharmacophore to bind to prostate specific membrane antigen.

HY-147057

Rofapitide tetraxetan 5+ Cited Publications FAP-2286	FAP	Cancer
Rofapitide tetraxetan (FAP-2286) is a potent and selective FAP-binding peptide with a mean IC₅₀ value of 2.7 nM for binding to FAP. Rofapitide tetraxetan can be labeled with radionuclides for diagnostic applications. Rofapitide tetraxetan has antitumor activity .

HY-W053583

*Tetraxetan* 1 Publications Verification DOTA	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Cancer
Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., ⁶⁸Ga, ¹¹¹In, ¹⁷⁷Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .

HY-43869

*Vipivotide tetraxetan* Ligand-Linker Conjugate** PSMA-617 Ligand-Linker Conjugate	ADC Linker	Cancer
Vipivotide tetraxetan Ligand-Linker Conjugate (PSMA-617 Ligand-Linker Conjugate) is a complex composed of pharmacophore group Glutamate-urea-Lysine peptide coupling linker, which can be used to synthesize Vipivotide tetraxetan (PSMA-617). Glutamate-urea-Lysine selectively binds to prostate-specific membrane antigen (PSMA) .

HY-P5128

DOTA-JR11 1 Publications Verification Satoreotide Tetraxetan	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research . DOTA-JR11 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-173374

DOTAGA-FAP-2286-ALB	FAP Drug Derivative	Cancer
DOTAGA-FAP-2286-ALB is a derivative of Rofapitide tetraxetan (HY-147057). DOTAGA-FAP-2286-ALB is a selective fibroblast activation protein (FAP) inhibitor with an IC₅₀ value of 67.5 nM. DOTAGA-FAP-2286-ALB enhances tumor retention via albumin interaction, prolonging blood circulation and improving radiometal complex stability (e.g., with 111In and 225Ac). DOTAGA-FAP-2286-ALB is promising for research of radionuclide therapy (TRT) of FAP-positive solid tumors .

HY-W053583R

Tetraxetan (Standard) DOTA (Standard)	Biochemical Assay Reagents Reference Standards Radionuclide-Drug Conjugates (RDCs)	Cancer
Tetraxetan (Standard) is the analytical standard of Tetraxetan (HY-W053583). This product is intended for research and analytical applications. Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., ⁶⁸Ga, ¹¹¹In, ¹⁷⁷Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .

HY-147057A

*Rofapitide tetraxetan* acetate** FAP-2286 acetate	FAP	Cancer
Rofapitide tetraxetan (FAP-2286) acetate is a potent and selective FAP-binding peptide with a mean IC₅₀ value of 2.7 nM for binding to FAP. Rofapitide tetraxetan acetate can be labeled with radionuclides for diagnostic applications. Rofapitide tetraxetan acetate has antitumor activity .

HY-P10905

Tezuvotide tetraxetan	Peptide-Drug Conjugates (PDCs)	Cancer
Tezuvotide tetraxetan is an antineoplastic peptide .

HY-159526

Adarulatide tetraxetan DOTA-AE105	Biochemical Assay Reagents	Others
Copper adarulatidum tetraxetanum (Copper adarulatide tetraxetan) is a diagnostic imaging agent .

HY-158077

(R)-tetraMe-Tetraxetan (R)-tetraMe-DOTA	Biochemical Assay Reagents	Others
(R)-tetraMe-Tetraxetanis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. (R)-tetraMe-Tetraxetan can be used for conjugation of peptides and radionuclides.

HY-153709

Zalsenertant tetraxetan IPN-01087	Neurokinin Receptor	Cancer
Zalsenertant tetraxetan (IPN-01087) is a DOTA-conjugated antagonist of the neurohypophyseal hormone receptor subtype 1 (NTSR1). Zalsenertant tetraxetan is labeled with the radioactive isotope Lu-177 (177Lu), which can be used for molecular imaging to identify potential responders. Zalsenertant tetraxetan can be used in the radiotherapy research of solid tumors .

HY-167790

2,3,5,6-Tetrafluorophenyl propionate-PEG3-amino-tetraxetan	Radionuclide-Drug Conjugates (RDCs)	Cancer
2,3,5,6-Tetrafluorophenyl propionate-PEG3-amino-tetraxetan is a chelating agent and linker conjugate that can be used in the synthesis of radiopharmaceuticals .

Cat. No.	Product Name	Type

HY-W053583

*Tetraxetan* 1 Publications Verification DOTA	Biochemical Assay Reagents
Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., ⁶⁸Ga, ¹¹¹In, ¹⁷⁷Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .

Tetraxetan

1 Publications Verification

DOTA

Biochemical Assay Reagents

Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., ⁶⁸Ga, ¹¹¹In, ¹⁷⁷Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .

HY-W053583R

Tetraxetan (Standard) DOTA (Standard)	Biochemical Assay Reagents
Tetraxetan (Standard) is the analytical standard of Tetraxetan (HY-W053583). This product is intended for research and analytical applications. Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., ⁶⁸Ga, ¹¹¹In, ¹⁷⁷Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .

Tetraxetan (Standard)

DOTA (Standard)

Biochemical Assay Reagents

Tetraxetan (Standard) is the analytical standard of Tetraxetan (HY-W053583). This product is intended for research and analytical applications. Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., ⁶⁸Ga, ¹¹¹In, ¹⁷⁷Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .

HY-158077

(R)-tetraMe-Tetraxetan (R)-tetraMe-DOTA	Biochemical Assay Reagents
(R)-tetraMe-Tetraxetanis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. (R)-tetraMe-Tetraxetan can be used for conjugation of peptides and radionuclides.

DOTA-JR11 1 Publications Verification Satoreotide Tetraxetan	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research . DOTA-JR11 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

Tezuvotide tetraxetan	Peptide-Drug Conjugates (PDCs)	Cancer
Tezuvotide tetraxetan is an antineoplastic peptide .

Adarulatide tetraxetan DOTA-AE105	Biochemical Assay Reagents	Others
Copper adarulatidum tetraxetanum (Copper adarulatide tetraxetan) is a diagnostic imaging agent .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.